TuHURA Biosciences (NASDAQ:HURA) Now Covered by Citizens Jmp

Citizens Jmp began coverage on shares of TuHURA Biosciences (NASDAQ:HURA) in a research note released on Monday morning, Marketbeat.com reports. The brokerage issued a market outperform rating and a $9.00 target price on the stock.

A number of other research firms also recently issued reports on HURA. Citigroup assumed coverage on TuHURA Biosciences in a research report on Monday. They issued an “outperform” rating on the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of TuHURA Biosciences in a research report on Tuesday, April 21st. Rodman & Renshaw initiated coverage on TuHURA Biosciences in a research note on Wednesday, April 15th. They issued a “buy” rating for the company. HC Wainwright reaffirmed a “buy” rating and set a $10.00 price target on shares of TuHURA Biosciences in a research report on Tuesday, February 3rd. Finally, Wall Street Zen cut TuHURA Biosciences from a “hold” rating to a “sell” rating in a research note on Saturday. Five research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $9.00.

TuHURA Biosciences Stock Down 5.5%

Shares of HURA stock opened at $2.22 on Monday. The company’s fifty day simple moving average is $1.92 and its 200-day simple moving average is $1.61. The firm has a market cap of $141.15 million, a PE ratio of -3.52 and a beta of -0.32. TuHURA Biosciences has a 12 month low of $0.41 and a 12 month high of $4.20.

TuHURA Biosciences (NASDAQ:HURA) last released its earnings results on Tuesday, March 31st. The company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.01). On average, equities analysts predict that TuHURA Biosciences will post -0.45 earnings per share for the current fiscal year.

Institutional Trading of TuHURA Biosciences

Institutional investors have recently added to or reduced their stakes in the company. PFG Investments LLC grew its holdings in TuHURA Biosciences by 39.4% in the 1st quarter. PFG Investments LLC now owns 32,630 shares of the company’s stock valued at $58,000 after buying an additional 9,219 shares in the last quarter. Apollon Wealth Management LLC grew its stake in shares of TuHURA Biosciences by 17.7% in the first quarter. Apollon Wealth Management LLC now owns 158,010 shares of the company’s stock valued at $283,000 after acquiring an additional 23,717 shares in the last quarter. Barclays PLC increased its position in TuHURA Biosciences by 42.6% during the fourth quarter. Barclays PLC now owns 52,615 shares of the company’s stock worth $40,000 after acquiring an additional 15,725 shares during the period. State Street Corp raised its stake in TuHURA Biosciences by 4.9% in the 4th quarter. State Street Corp now owns 289,133 shares of the company’s stock worth $219,000 after purchasing an additional 13,594 shares in the last quarter. Finally, Wells Fargo & Company MN raised its stake in TuHURA Biosciences by 109.0% in the 4th quarter. Wells Fargo & Company MN now owns 38,208 shares of the company’s stock worth $29,000 after purchasing an additional 19,931 shares in the last quarter. 0.62% of the stock is currently owned by institutional investors.

About TuHURA Biosciences

TuHURA Biosciences is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics using high‐dimensional proteomics. The company’s core mission is to translate complex protein signatures into actionable drug targets across a range of disease areas. By integrating proteomic data with advanced computational analytics, TuHURA aims to bridge the gap between molecular disease understanding and the development of first‐in‐class therapies.

At the heart of TuHURA’s approach is its proprietary platform, which leverages multiplexed protein profiling to generate rich phenotypic maps of disease states.